Work Here?
Overview
Alector is a biopharmaceutical company that develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It uses insights from immunology, neurology, and human genetics to create medicines that help the body heal itself. The company focuses on researching and developing novel therapeutic candidates, mainly through early-stage clinical trials to quickly gather disease-specific data and improve the chances of success. Revenue and funding come from partnerships, grants, and eventual product commercialization. Alector aims to advance treatments for unmet medical needs in neurodegenerative diseases by pursuing a pipeline that combines scientific findings with strategic drug development.
About Alector
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2013
Get referred to Alector
See people who can refer or advise you
Simplify's Take
What believers are saying
- Alector held $172.8 million at June 30, 2026, funding operations through 2027.
- Q2 2026 losses narrowed, and operating expenses fell after 2025 restructurings.
- AL137 advances through IND-enabling studies, with submission targeted for Q1 2027.
What critics are saying
- GSK ended the collaboration July 6, 2026, effective January 2, 2027.
- AbbVie already terminated AL002 after INVOKE-2 failed in November 2024.
- AL137 is the existential bet; a Q1 2027 IND miss crushes the story.
What makes Alector unique
- Alector’s ABC platform combines antibody delivery with neuroimmunology and human genetics.
- AL137, AL050, and AL164 target Alzheimer’s, Parkinson’s, and tauopathy through one platform.
- Lean outsourcing structure keeps headcount light and lets Alector redeploy capital quickly.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$495.5M
Above
Industry Average
Funded Over
6 Rounds
Benefits
Flexible Work Hours
Hybrid Work Options
Stock Price
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↑ 1%2 year growth
↑ 4%Alector reported a first-quarter loss of $0.21 per share, beating the consensus estimate of a $0.35 loss by 40%. This marks the fourth consecutive quarter the biotechnology company has surpassed earnings expectations. The result improved from a loss of $0.41 per share in the same period last year. However, the company missed revenue targets, posting $1.05 million against expectations of $3 million, a 65.13% shortfall. This compares to revenue of $3.67 million in the year-ago quarter. Alector shares have gained 64.7% year-to-date, outperforming the S&P 500's 7.6% gain. Despite the earnings beat, unfavourable estimate revisions have resulted in a Zacks Rank of four, suggesting potential near-term underperformance.
Alector, a South San Francisco-based biotechnology company, reported a fourth-quarter loss of $37.3 million, or 34 cents per share, beating analyst expectations of a 39-cent loss. The company posted revenue of $6.2 million, exceeding forecasts of $3.1 million from three analysts surveyed by Zacks Investment Research. For the full year, Alector's loss widened to $142.9 million, or $1.39 per share, with revenue of $21 million. The company's shares closed at $2.39 on Wednesday, up from $1.77 a year earlier.
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.About AlectorAlector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline
Additionally, Alector will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025, at 12:00 p.m. ET.
In another strategy, Alector, in collaboration with GSK, is developing the monoclonal antibody latozinemab (AL001), which works by blocking progranulin degradation to boost its availability.
Alector is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Alector
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2013
Alector is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today